Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome
Clinical Trial Grant
Administered By
Psychiatry, Child & Family Mental Health & Community Psychiatry
Awarded By
Neurocrine Biosciences, Inc.
Start Date
October 24, 2018
End Date
September 30, 2020
Administered By
Psychiatry, Child & Family Mental Health & Community Psychiatry
Awarded By
Neurocrine Biosciences, Inc.
Start Date
October 24, 2018
End Date
September 30, 2020